

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company a⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$7.86
Price-0.25%
-$0.02
$1.251b
Small
-
Premium
Premium
-581.2%
EBITDA Margin-580.2%
Net Profit Margin-532.4%
Free Cash Flow Margin$93.946m
-13.3%
1y CAGR+995.8%
3y CAGR+724.1%
5y CAGR-$129.874m
-33.9%
1y CAGR-12.7%
3y CAGR-17.6%
5y CAGR-$0.90
-28.6%
1y CAGR+5.2%
3y CAGR+7.2%
5y CAGR$147.140m
$252.355m
Assets$105.215m
Liabilities$21.711m
Debt8.6%
-0.2x
Debt to EBITDA-$200.117m
-31.7%
1y CAGR-195.7%
3y CAGR-157.9%
5y CAGR